Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 13/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744745 | 0.90 | CXCL12 (0.49) | ABCB1MAPTNPSR1ABCG2 | |
| SCHEMBL7033020 | 0.90 | MAPT (0.61) | ABCB1MAPTNPSR1 | |
| SCHEMBL764043 | 0.90 | MAPT (0.61) | ABCB1MAPTNPSR1 | |
| SCHEMBL746535 | 0.90 | ABCB1 (0.52) | ABCB1MAPTNPSR1ABCG2 | |
| SCHEMBL744504 | 0.90 | ABCG2 (0.57) | ABCB1MAPTNPSR1ABCG2 | |
| SCHEMBL743874 | 0.89 | ABCB1 (0.57) | ABCB1MAPTNPSR1ABCG2 | |
| SCHEMBL748316 | 0.86 | NFKB1 (0.52) | ABCB1MAPTNPSR1ABCG2 | |
| SCHEMBL743365 | 0.85 | TXNRD1 (0.60) | ABCB1MAPTNPSR1 | |
| SCHEMBL749682 | 0.85 | TDP1 (0.56) | ABCB1MAPTNPSR1ABCG2 | |
| SCHEMBL744994 | 0.85 | MAPT (0.49) | ABCB1MAPTNPSR1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429292-B1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | GEORGIA STATE UNIV RESEARCH FOUNDATION (US) | 2019-04-03 | — | — | EP | claimed |
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | SHANDONG UNIVERSITY (CN) | 2012-05-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121692-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING CDK INHIBITORS AND METHODS FOR TREATING CANCER | CDK6, CDK5, CDK4 | ABCB1 2307/4885MAPT 3525/4885NPSR1 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.